Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer

C M BATE, S P WILKINSON, G V H BRADBY, M C BATESON,
W S HISLOP, J P CROWE, C P WILLOUGHBY, E M PEERS,
AND P D I RICHARDSON

From the Royal Albert Edward Infirmary, Wigan; Gloucestershire Royal Hospital, Gloucester; Sandwell District General Hospital, W Bromwich; The General Hospital, Bishop Auckland; Royal Alexandra Hospital, Paisley; Mater Misericordiae Hospital, Dublin; Basildon Hospital, Basildon; Astra Pharmaceuticals Ltd, Kings Langley, Herts

SUMMARY In a randomised, double blind, parallel group study in patients with symptomatic gastric ulcer (94% ≥ 5 mm diameter), 102 received omeprazole 20 mg om and 87 cimetidine 400 mg bd. After four weeks 73% and 58% ($p < 0.05$) respectively had healed (eight weeks: 84% and 75%, ns). After four weeks, a greater proportion (81%) of omeprazole treated patients was symptom free than of those receiving cimetidine (60%; $p < 0.01$). Over the first two weeks, patients receiving omeprazole had less day pain, less night pain and took fewer antacids than those receiving cimetidine (all $p < 0.05$). The difference between omeprazole and cimetidine was not appreciably affected by age, smoking, size of the ulcer and trial centre. Tolerability was similar in the two treatment groups. In the treatment of symptomatic gastric ulcer, omeprazole relieves the symptoms more quickly than cimetidine and heals a greater proportion of ulcers within four weeks.

Omeprazole specifically inhibits $H^+K^+-ATPase$, the 'proton pump' in the parietal cell¹ thereby effectively controlling gastric acid secretion.² Whilst 20 mg om omeprazole has been shown to heal a greater proportion of duodenal ulcers within two and four weeks than H_2 -receptor antagonists,³ there have been fewer studies in patients with gastric ulcer.⁴⁻⁶ One⁴ showed similar efficacy of omeprazole and ranitidine but included small ulcers which healed quickly on both regimens; two others^{5,6} showed that omeprazole 20-40 mg healed gastric ulcers more quickly than ranitidine 150 mg bd.

The present study was designed to compare omeprazole 20 mg om with cimetidine 400 mg bd on both the healing and the relief of symptoms of gastric ulcer. Particular attention was directed to the time course of the relief of symptoms with the two drugs.

Methods

TRIAL DESIGN

The trial was a randomised double blind parallel group comparison of omeprazole 20 mg om and cimetidine 400 mg bd in 16 centres in the UK and the Republic of Ireland. Details of recruitment are given at the end of the paper: 13 centres were in the gastroenterology units of district hospitals and three involved local general practitioners in the treatment (but not endoscopic assessment) of patients. Blindness was maintained by the 'double dummy' technique: patients took either one active 20 mg omeprazole capsule each morning and one placebo tablet morning and evening or one placebo capsule each morning and one 400 mg cimetidine tablet morning and evening. At randomisation, patients were stratified by age (< 65 ; ≥ 65) and smoking (current smoker; non-smoker) for prospectively defined subgroup analyses; separate sets of drug packs were used for each of the four subgroups.

Address for correspondence: Dr C M Bate, Royal Albert Edward Infirmary, Wigan Lane, Wigan, Lancs WN1 2NN

Accepted for publication 9 February 1989.

Compliance was assessed by tablet counts, by enquiry by the physicians, and patients recorded each day on diary cards whether or not they had taken their tablets and capsules as directed.

Patients aged 18–80 were eligible for the study if they had a symptomatic gastric ulcer [GU] confirmed by endoscopy within the three days prior to randomisation. Prepyloric ulcers were included and identified as such if the centre of the ulcer crater was within 3 cm of the pylorus. Ulcer size was measured using biopsy forceps and at entry a minimum ulcer diameter of 5 mm was recommended.

Patients were excluded if they were pregnant, at risk of pregnancy, lactating, and if they had pyloric stenosis, oesophageal abnormalities, active gastro-intestinal bleeding, previous surgery of the stomach or duodenum (or vagotomy), or severe concurrent disease. Other exclusions were the use of H₂-receptor antagonists or other antisecretory drugs for more than two days in the two weeks before endoscopy and randomisation, the use of anticoagulants, theophylline, phenytoin or NSAIDs, and unwillingness to participate. The trial received ethical approval at each institution.

Symptoms were recorded (as mild, moderate or severe) by the physician at entry and after four weeks [26–30 days] and eight weeks [52–60 days: only if the ulcer was unhealed after four weeks] treatment. Endoscopy was repeated at these times and healing was defined as complete re-epithelialisation of all ulcer craters. Patients completed daily diary cards recording whether or not the trial medication was taken, the presence or absence of day and night pain, and the number of antacids taken [Rennies, Nicholas, were provided and taken prn].

Adverse events were elicited by response to an open question and by examination of the case record books. Blood and urine tests were performed at entry and at the patients' final visits.

Biopsies were taken at the initial endoscopy, and if malignancy was detected but reported after randomisation the patients were withdrawn immediately; these patients are excluded from the efficacy analyses.

ANALYSES

Analyses of ulcer healing were carried out on an intention-to-treat basis where missing patients are assumed to be unhealed. Symptomatic data were analysed as the proportion of available patients at any particular time. The trial was designed to have a power of 80% to detect a 20% difference in healing rates at $p < 0.05$ if 190 patients completed the trial.

Differences in healing rates between the treatment groups were assessed using Mantel-Haenszel tests to take into account the stratification at randomisation. Symptomatic data recorded by enquiry at clinic visits

were assessed using Wilcoxon's tests stratified for pretreatment symptoms. A multivariate logit analysis was conducted to estimate the influence of prognostic factors on healing rates. Differences in day pain, night pain and antacid consumption, recorded on diary cards over the first two weeks of the trial, between the two treatment groups were assessed using the Kolmogorov-Smirnov test. Data are expressed as means (SD) or with 95% confidence intervals (CI); p values > 0.05 are regarded as non-significant (ns).

Results

PATIENT CHARACTERISTICS

One hundred and ninety seven patients were randomised, 105 to receive omeprazole and 92 to receive cimetidine (29 and 21 respectively had prepyloric ulcers). In addition, one patient died after randomisation but before taking any trial medication and is excluded from all analyses. At randomisation, the groups were well balanced (Table 1). Patients were also comparable in the drugs that they were taking before and during the trial.

ENDOSCOPY AT ENTRY

Table 2 shows the number of gastric ulcers, the diameter of the 'index ulcer' – the sole or largest ulcer – (> 5 mm in 94% of patients) and other findings. The two treatment groups were comparable at entry.

PATIENTS ANALYSED

Eight patients were withdrawn because of reports of malignancy, three from the omeprazole group and

Table 1 Patient characteristics at randomisation

	Omeprazole	Cimetidine
Patients (n)	105	92
Sex (M:F)	49:56	44:48
Age (65:65)	71:34	58:34
Age (yrs)	57 (14)	57 (13)
Weight (kg)	66 (14)	66 (13)
Height (cm)	165 (9)	164 (9)
Smokers (yes:no)	63:42	54:38
BP (mmHg)	131 (18)	134 (21)
	79 (11)	80 (12)
HR (beats/min)	76 (9)	79 (8)
Duration of ulcer symptoms (yrs)	5.7 (9.2)	4.7 (8.8)
Duration of proven ulcer disease (yrs)	1.6 (5.4)	1.5 (4.5)
Duration of current symptomatic episode (wk)	17 (47)	13 (16)
Episodes in last year (n)	4.2 (7.3)	3.1 (5.3)
Previous complications of ulcer disease*	5	4

*Bleeding, melana: data are shown as numbers of patients except where units are specified. Data expressed as means (SD).

Table 2 Endoscopy findings at entry

	Omeprazole Patients (n)	Cimetidine Patients (n)
Ulcers (n):		
1	82	73
2	20	10
3	1	5
3	2	4
Size of index ulcer:		
<5 mm	7	5
5–10 mm	67	59
11–20 mm	24	22
20 mm	5	3
unknown	2	3
Hiatus hernia	3	2
Oesophagitis	3	1
Gastritis	3	6
Duodenitis	5	8

five from the cimetidine group. The analyses are therefore carried out on 102 patients receiving omeprazole and 87 receiving cimetidine. After four weeks, data were available for 173 (92%) patients and after eight weeks 169 (89%).

ULCER HEALING – OVERALL

After four weeks' treatment, 74/102 (73%) of the

Fig. 1 Proportions of patients with gastric ulcers healed after four and eight weeks treatment with cimetidine 400 mg bd (open bars) or omeprazole 20 mg om (shaded bars). $p < 0.05$ at four weeks.

patients receiving omeprazole had healed ulcers compared with 50/87 (58%; $p < 0.05$) of those receiving cimetidine (Fig. 1). The therapeutic gain, or difference between the percentages of patients healed, is 15% (CI +1 to +29%). The corresponding cumulative figures after eight weeks were 86/102 (84%) and 65/87 (75%; $p = 0.1$) with a therapeutic gain of 9% (CI -2 to +21%).

Fig. 2 Healing rates in subgroups prospectively defined and stratified for smoking and age, and for patients with index ulcer sizes above and below the median of 10 mm. Presentation as in Figure 1. Numbers in parentheses are the number of patients in each subgroup.

ULCER HEALING – SUBGROUPS

Smoking

Overall smokers had a smaller proportion of ulcers healed at four ($p<0.05$) and eight (ns) weeks than non-smokers. In each subgroup the proportion of ulcers healed in patients receiving omeprazole was greater than in those receiving cimetidine (Fig. 2a).

Age

Age did not affect overall healing rates significantly. Generally the healing rates were higher in the omeprazole than cimetidine groups (Fig. 2b).

Ulcer size

Groups were formed retrospectively for those with an index ulcer under the median diameter of 10 mm and those ≥ 10 mm. A greater proportion of ulcers in the group with smaller ulcers healed after four weeks ($p<0.05$) than those in the group with larger ulcers. In each subgroup, a greater proportion of the ulcers treated with omeprazole healed compared with those treated with cimetidine (Fig. 2c).

ULCER HEALING – PROGNOSTIC FACTORS

In an initial logit analysis, alcohol consumption, sex, number of ulcers, history of ulcer disease and number of episodes of ulcer symptoms had no prognostic effect on healing. In the final model, treatment (omeprazole or cimetidine) had a significant prognostic effect as did ulcer size and smoking, notably after four but not eight weeks. Trial centre and age

did not significantly affect the prognosis for GU healing.

PREPYLORIC ULCERS

Healing rates for prepyloric ulcers were similar to the whole group: at four weeks, 11/19 (58%) treated with cimetidine and 22/28 (79%) with omeprazole had healed. The corresponding figures for corporeal ulcers were 57% and 70% respectively.

SYMPTOMS – CLINIC VISITS

At entry, all but two patients reported symptoms. After four weeks, 81% of patients receiving omeprazole reported no symptoms compared with 60% receiving cimetidine ($p<0.01$). After eight weeks, the difference (Fig. 3) was no longer significant.

Patients were questioned about specific symptoms at clinic visits. After four but not eight weeks, those in the omeprazole group reported less daytime pain and heartburn ($p<0.05$) than those in the cimetidine group. There was no difference in nocturnal pain or nausea. Too few patients suffered vomiting, haematemesis, melaena or other symptoms for meaningful analysis.

SYMPTOMS – DIARY CARDS

After four weeks (Fig. 3) the majority of patients did not experience pain on either regimen. Complete diary card data available from 80–83% of randomised patients in each group, however, reveal that from days 2 to 14 inclusive fewer patients in the omeprazole group than the cimetidine group had day pain (Fig. 4, left panel: $p<0.01$), or night pain (Fig. 4, right panel: $p<0.05$), and patients in the omeprazole group took fewer antacids ($p<0.0001$).

In a stricter analysis of patients whose symptoms disappeared, defined as patients without pain who took no antacids, a greater proportion of those receiving omeprazole than cimetidine had relief of symptoms (Fig. 5: $p<0.001$).

SAFETY

In the omeprazole group, 19/102 (19%) and in the cimetidine group 13/87 (15%) patients had adverse experiences. Two adverse experiences were classified as serious, both in the omeprazole group; neither was regarded as drug related (one left ventricular failure (LVF) presumed secondary to ischaemic heart disease, and one with LVF treated before the trial, a urinary tract infection and dehydration, nausea, dyspnoea, and vomiting). Seven more patients (four in the omeprazole group; two of these complained of persisting ulcer symptoms and were included as adverse experiences in this study) withdrew because of adverse events. Table 3 gives details of the adverse events by system. No excess of out-of-range values in

Fig. 3 Proportion of patients reporting pain of varying severity at clinic visits. At entry, 19% in each group had mild pain, 45% moderate and 35% severe pain.

Fig. 4 Proportion of patients reporting day and night pain during the first two weeks of omeprazole or cimetidine treatment.

either group was detected by analysis of blood taken at the start and end of treatment (the measurements were: haemoglobin, haematocrit, WBC, platelets, creatinine, bilirubin, alkaline phosphatase, ALAT, ASAT, sodium, potassium, calcium) or by urine tests (glucose, protein).

Discussion

Previous reports of the effects of omeprazole on gastric ulcers have concentrated on endoscopic assessments^{1,5} and have shown that omeprazole 20 mg om is at least as effective⁴ or more effective⁶ than ranitidine. The present study shows that this dose of omeprazole,^{2,7} which does not cause complete 24 h suppression of gastric acid secretion in volunteers, not only heals a greater proportion of gastric ulcers than cimetidine over a four week period, but also

relieves the symptoms more rapidly. We are confident in the symptomatic findings because both clinic questions and diary cards gave consistent information, diary cards were completed accurately by over 80% of patients in both treatment groups, and the differences between omeprazole and cimetidine are consistent in terms of both pain relief and antacid consumption.

More rapid healing of gastric ulcers occurred in all subgroups treated with omeprazole than those receiving cimetidine. The prospective stratification for age and smoking resulted in comparable numbers of patients treated with each drug in the subgroups. Age did not seem to affect healing rates consistently, but fewer smokers, especially in the cimetidine group, healed within four weeks than non-smokers. After eight weeks, the rate of ulcer healing with cimetidine was similar to that with omeprazole after four weeks. As might be expected, the smaller ulcers tended to heal more rapidly than larger ulcers on

Fig. 5 Proportion of patients who were both free of pain and did not take any antacids during the first two weeks of treatment.

Table 3 Summary of adverse events

System	Omeprazole	Cimetidine
CNS	7	3
Endocrine	0	1
Circulatory	1	0
GI:		
pain	4	0
vomiting	2	1
diarrhoea	5	3
constipation	0	2
Urinary	0	2
Musculoskeletal	1	1
Skin rashes	0	2
Respiratory	1	0

Within each category, such as CNS, there was a mixture of symptoms. Adverse events, such as GI pain, include comments made in the record books as well as responses by patients to questions.

both treatments but even in the patients with large ulcers, omeprazole healed 65% within four weeks (cimetidine=45%). In this study prepyloric ulcers behaved in much the same way as corporeal ulcers and did not exhibit the very high healing rates seen in another study,⁸ although the numbers of patients with prepyloric ulcers in the present study was too small to make firm conclusions.

After eight weeks' treatment, the differences between the two drugs became smaller, as would be expected, and this trend was seen in all subgroups. A minimum of eight weeks' treatment with cimetidine has been proposed for treating gastric ulcer with continuation to 16 weeks if necessary.⁹ In contrast, four weeks' treatment with 20 mg omeprazole once daily results in gastric ulcer healing rates of 70–80%. Omeprazole and cimetidine were similarly well tolerated.

The results of the present trial support the view that a correlation may exist between the control of acid secretion and the healing of gastric ulcers.¹⁰ It seems likely that there is enhanced control of acid secretion with omeprazole which results not only in faster healing of the ulcer crater but also in more rapid symptom relief.

Patients were recruited by the following physicians: C M Bate (36), S P Wilkinson (24), G V H Bradby (24), M C Bateson (21), W S Hislop (18), J P Crowe (12), C P Willoughby (10), the Department of General Practice at Glasgow (Prof J H Barber, Dr G P Crean, 11), M B McIlmurray (Lancaster, 9), the Department of General Practice at St George's, London (Prof P Freeling, Dr T C Northfield, 8), Dr R W Crofton (Carlisle, 6), Dr M O Rake (Canterbury, 6), Dr M J Dew (Llanelli, 5), the Department of General Practice at Cardiff (Prof R Harvard Davis, Prof N C H Stott, Dr P M Smith, Dr B W Lawrie, 4), Dr R H Teague (Torquay, 2), and Dr P G Wheeler (Ashford, 2).

Miss Alison Scrimgeour analysed the trial and Miss Pam Soan prepared the manuscript.

References

- 1 Fellenius E, Berglin T, Sachs G, *et al.* Substituted benzimidazoles inhibit gastric acid secretion by blocking (H⁺, K⁺)ATPase. *Nature* 1981; **290**: 159–61.
- 2 Lind T, Cederberg C, Ekenved G, Haglund K, Olbe L. Effect of omeprazole – a gastric proton pump inhibitor – on pentagastrin stimulated acid secretion in man. *Gut* 1983; **24**: 270–6.
- 3 Bardhan KD, Bianchi Porro G, Bose K, *et al.* A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. *J Clin Gastroenterol* 1986; **8**: 408–13.
- 4 Classen M, Dammann H-G, Domschke W, *et al.* Omeprazole heals duodenal but not gastric ulcers more rapidly than ranitidine. *Hepatogastroenterology* 1985; **32**: 243–5.
- 5 Walan A, Bader JP, Classen M, *et al.* Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. *N Engl J Med* 1989; **320**: 69–75.
- 6 Barbara L, Saggioro A, Olsson J, Cisternino M, Franceschi M. Omeprazole 20 mg om and ranitidine 150 mg bd in the healing of benign gastric ulcers [Abstract]. *Gut* 1987; **28**: A1341.
- 7 Sharma BK, Walt RP, Pounder RE, Gomes MdeFA, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. *Gut* 1984; **25**: 957–64.
- 8 Lauritsen K, Rune SJ, Wulff HR, *et al.* Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. *Gut* 1988; **29**: 249–53.
- 9 Graham DY, Akdamar K, Dyck WP, *et al.* Healing of benign gastric ulcer: comparison of cimetidine and placebo in the United States. *Ann Intern Med* 1985; **102**: 573–6.
- 10 Howden CW, Jones DB, Peace KE, Burget DW, Hunt RH. The treatment of gastric ulcer with antisecretory drugs: relationship of pharmacological effect to healing rate. *Dig Dis Sci* 1988; **33**: 619–24.